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Summary To test the anti-tumour activity of rhizoxin in recurrent and/or metastatic squamous cell head and
neck cancer, we performed a phase II study. Eligibility required histologically proven squamous cell head and
neck cancer. Patients could only have received one prior chemotherapy. Patients were entered if WHO PS was
,<2 and organ functions were normal. Treatment consisted of rhizoxin 1.5-2.0 mg m-2 i.v. bolus injection
once every 3 weeks. Thirty-two patients entered the study. All were eligible, 31 were evaluable for toxicity and
25 for response. Toxicity mainly consisted of pain at the tumour site and leucocytopenia. Mild asthenia and
stomatitis were also observed. Two objective partial responses, lasting 7.5 and 3.5 months, were seen. Rhizoxin
at this dose and schedule has minor activity in recurrent and/or metastatic squamous cell head and neck cancer.
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The incidence of head and neck cancer in Europe is about 35
per 100 000 per year in males and 5 per 100 000 in females.
The vast majority ofhead and neck tumours are of squamous
cell type. Curative treatment for disease of limited extension
consists of radiation therapy and/or surgery. The failure rate
of curative treatment varies with the extension of the disease
and the origin of the tumour. Five year survival rates may
also vary considerably depending on the extension and
primary site, with lowest values less than 25% and highest
values more than 75%. Chemotherapy is used in the
treatment of squamous cell carcinoma of the head and neck
either as the only therapeutic modality for advanced or
recurrent tumours or as part of a multimodality approach.
The chemotherapy regimens most widely used consist of
combinations of methotrexate and bleomycin, and more
recently, cisplatin or other agents, with response rates in
locally advanced disease equal or greater than 50%, but in
metastatic disease only 10-25%.
The response and survival of squamous cell carcinoma of
the head and neck to chemotherapy may be considerably
influenced by characteristics of the patients and/or the
tumour, such as performance status, prior therapy, site of
origin of the tumour and possibly histological differentiation
(Clavel and Mansour, 1991).
In view of the high recurrence rate after induction
chemotherapy and the low response rate in metastatic
disease, the screening of potentially useful drugs in
squamous cell carcinoma of the head and neck is warranted
and might lead to improve current treatment of this frequent
tumour.
Rhizoxin is a 16-membered macrocyclic lactone with
antifungal activity (Iwasaki et al., 1984; Kiyoto et al.,
1986). It is produced by and isolated from the pathogenic
fungus Rhizopus chinensis, which causes rice seedling blight.
The drug has a molecular weight of 625.8 and is poorly
soluble (< 1 mg ml-') in water and hydro-alcoholic vehicles,
but very soluble (> 100 mg ml-') in organic solvents such as
alcohols, dimethyl sulphoxide and chloroform. Rhizoxin has
shown activity in vitro and in vivo in a wide variety of tumour
models (Matsuda et al., 1984; Hendriks et al., 1992).
Rhizoxin inhibits the mitosis of tumour cells in a way
similar to vincristine and maytansine (Tsuruo, 1986;
Takahashi, 1987), with a resulting cell cycle block in the
G2/M phase. Binding studies showed that rhizoxin bound to
the vincristine binding site and not the colchicine binding site,
inhibiting polymerisation of tubulin. The drug was also active
in several cell lines resistant to vincristine (Tsuruo et al.,
1986). In vitro studies have shown that an intermittent
administration of the drug induced a significantly better
tumour growth inhibition than a daily dose schedule
(Hendriks et al., 1992).
In a phase I study using an intravenous bolus adminis-
tration patients were treated with doses ranging from 0.8 to
2.6 mg m-2 single dose every 3 weeks (Bissett et al., 1992).
The dose-limiting toxicities were mucositis, diarrhoea,
leucopenia, neutropenia and thrombocytopenia. Other toxi-
cities observed were fever, peripheral neuropathy (PNP),
hepatic toxicity, headache, rash and change in taste, all mild
and infrequent. Alopecia was also noticed. All patients
experienced mild to moderate local discomfort during the
injection of rhizoxin, although phlebitis occurred in only
three patients. Three patients with breast cancer showed an
objective response. The dose recommended for phase II
studies was 2.0 mg m-2 given every 3 weeks.
The EORTC Early Clinical Trials Group performed a
phase II study in patients with metastatic or locoregionally
advanced squamous cell cancer of the head and neck.
Patients and methods
Eligibility
Eligibility criteria included histologically or cytologically
verified, uni- or bidimensionally measurable, locally ad-
vanced, unresectable or metastatic squamous cell carcinoma
of the head and neck, WHO performance status <2, age
> 18 years; and adequate bone marrow (WBC>4000 ul
platelets,> 100 000 MIl-1), hepatic and renal function.
Patients must not have received more than one
chemotherapy regimen for advanced disease prior to entry
in the study, while a minimum of 4 weeks was required
between last dose of previous treatment and study treatment.
Previous radiotherapy was permitted provided it did not
involve the only measurable lesion, unless this lesion had
newly arisen in a previously irradiated field. Informed
consent had to be obtained and documented according to
the local regulatory requirements and the rules followed at
each institution.
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Treatment
Rhizoxin was supplied as vacuum white to off-white dried
powder in 10 ml amber vials. Each vial contained 5 mg of
rhizoxin, 25 mg of mannitol (USP), and 25 mg ascorbic acid
(USP). Rhizoxin vials were delivered in a duo-pack, which
also contained special 2.5 ml sterile diluent vials containing
80% (v/v) propylene glycol and 20% (v/v) ethanol.
After reconstitution and after complete dissolution was
obtained 2.5 ml of sterile water for injection had to be added.
The resulting solution thus contained: rhizoxin 1 mg ml-' in
40% propylene glycol (v/v), 10% ethanol (v/v) in sterile water
for injection. Initially rhizoxin was administered at a dose of
2 mg m-2 by a single bolus i.v. injection once every 3 weeks.
It was to be administered directly into the vein, not into a
running drip, as it precipitates in saline and dextrose
solutions. The cannula should be flushed through afterwards
with 1 cc of the special diluent.
Treatmenthad to be delayed by 1 week ifWBC and platelets
at the scheduled day ofretreatment were <3.0 x 109 l-l and/or
<100 x 19 1- I respectively. In this case the next course was to
be given at 75%. Dose reductions to 75% were also made ifthe
preceeding course wascomplicated by adocumented episode of
either bleeding with thrombocytopenia or febrile neutropenia
requiring hospitilisation.
For patients who developed >grade 3 non-haematological
toxicity, the decision to have their therapy reduced to 75% or
withheld dependend upon the investigator's judgement.
Patients whose treatment was delayed for more than 2
weeks were removed from the study.
During the course of the study, because of observed side-
effects, the starting dose of rhizoxin was amended to
1.5 mg m-2 once every 3 weeks for patients who had prior
radiotherapy. In case of less than grade 3 haematological
toxicity and less than grade 2 mucositis the dose should
subsequently be increased to 2.0 mg m-2
Follow-up studies
Prior to entry, history and physical examination were
performed, as well as assessment of haemoglobin, WBC,
differential, platelets, serum creatinine and biochemistry
including at least Na+, K+, Ca2+, albumin, bilirubin,
ASAT, ALAT, alkaline phosphatase, and LDH. In addition
urinalysis, chest radiograph and radiographics for tumour
measurements were performed. During the study history,
physical examination, haematology and biochemistry were
repeated every three weeks. After the amendment regarding
the starting dose, haematology parameters were taken
weekly. Tumour measurements and the related diagnostics
were repeated every two courses.
Evaluation
All patients were eligible, one did not start treatment.
Toxicity was graded according to CTC criteria. Patients
were scheduled to receive at least two doses of rhizoxin, and
to assess activity at least 14 evaluable cases were required.
Response was assessed by repeated clinical and radiological
examinations as appropriate, using WHO criteria. Patients
demonstrating evident tumour progression after 3 weeks were
taken off study and classified as 'early progression'. The
duration of partial response or no change dated from the
commencement of treatment until the documentation of
progression. The duration of survival was dated from the
initiation of treatment.
Results
A total of 32 patients were entered into the study. Patient
characteristics are given in Table I. Thirty-one patients were
evaluable for toxicity. Six patients could not be evaluated for
response, all because of early treatment discontinuation due
to toxicity. This left 25 patients evaluable for response.
Table I Patient characteristics













A total of 89 treatment doses were given with a median
number of 2 (range 1-11). Responses are given in Table II.
Two partial remissions, assessed by CT scan, were observed
and confirmed by extramural review. Response duration was
7.5 and 3.5 months respectively. The overall response rate
regarding evaluable patients is 8% (95% confidence interval
1-26%). This response rate is 6% regarding all treated
patients. One of these responses was documented in a 32-
year-old patient suffering from a large ulcerated cervial
recurrence of a tongue carcinoma. Rhizoxin was started after
documentation of disease progression during carboplatin-
5FU chemotherapy. An 82% tumour regression was observed
during rhizoxin therapy. This response lasted for 10 weeks.
The second responding patient was treated with neo-adjuvant
chemotherapy and radiotherapy for a large squamous cell
carcinoma of the tongue, and by surgery and radiotherapy at
local recurrence 1 year later. The patient then developed
cervical lymph node metastases and obtained a partial
remission, assessed by CT scan, with rhizoxin. All but one
of the 17 courses of rhizoxin given to the responding patients
were given at the dose of 1.5 mg m-2.
The most intriguing side-effect of rhizoxin was a severe
pain at the tumour site, that could hardly be controlled by
intravenous morphines. It occurred mainly in the first cohort
ofpatients treated and led to the amendment in starting dose
indicated above. Thirty-four courses were given at the dose of
2.0 mg m-2, all others at lower doses. After lowering the
starting dose the side-effect was no longer observed. In total
it was seen in 9 of the 32 patients treated (28%), six ofwhom
were taken off the study because of this toxicity.
Further treatment was well tolerated. Haematological
toxicity was moderate and consisted of leucocytopenia
grades 1-2 in 35 administrations (39%) and grades 3-4 in
15 courses (17%), while thrombocytopenia grades 1-3 was
noticed in three courses (3%). Although not required per
protocol, in 82 of the 89 courses laboratory tests were
performed weekly, so for this particular study the above data
reflect the actual haematological toxicity. Leucocytopenia
appeared to be short-lasting. Non-haematological toxicity
consisted of mild to moderate phlebitis in 23 courses (26%),
asthenia in 24 courses (27%) and stomatitis in 28 courses
[31%; six courses (7%) grades 3-4]. Alopecia was noted in
26 patients (84%). In only six courses did patients experience










CR, complete response; PR, partial response; NC, no change; PD,
progressive disease; NE, not evaluable.
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Discussion
Rhizoxin has an interesting preclinical profile of anti-tumour
activity. A phase I study revealed neutropenia, thrombope-
nia, mucositis and diarrhoea as dose-limiting toxicities
(Bissett et al., 1992). In the presently reported phase II
study, treatment was initially poorly tolerated due to a
remarkably severe pain, occurring at tumour sites previously
treated with radiotherapy and unrelievable by any analgetic
treatment, including intravenous morphines, but reduction of
the starting dose resulted in complete disappearance of this
side-effect. Similar observations were made in head and neck
cancer patients treated with vinca alkaloids. The pathogenetic
mechanism related to the observed pain in the tumour sites
will need to be elucidated. This side-effect was not noted in
patients who had undergone previous radiotherapy for other
diseases, but in most of these diseases radiation doses were
lower than the common dose used in the treatment of head
and neck cancer. Whether the radiation dose has any relation
to the observed side-effect cannot be stated for certain,
because of the small sample size. Other reasons for poor
tolerance were severe mucositis and febrile neutropenia in the
first few patients treated at the initial starting dose. After
reduction of the starting dose, treatment was well tolerated
with a 56% occurrence of mainly uncomplicated leucocyto-
penia, mild asthenia (27%) and stomatitis (31%). Thrombo-
cytopenia and diarrhoea, dose-limiting toxicities in the phase
I study, were only seen in 3% and 7% of the head and neck
cancer patients. These lower incidences could be partly
related to the lower doses used in the present study.
Only two objective partial remissions (8%) were achieved.
Although the preclinical studies did not show any schedule
dependency, other schedules may result in better locoregional
tolerability and in theory may enable higher doses with
higher response rates. This should first be explored in models
attempting to unravel the mechanism behind the tumour
pain.
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